Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Sep 28, 2021 1:00 PM - Sep 30, 2021 5:30 PM

(Central Europe Standard Time)

Accelerating CMC Workshop

Innovation and Convergence in a post COVID-19 world

Session 6: ICH Expansion and the Journey towards Harmonisation

Session Chair(s)

Frank  Montgomery, PhD

Frank Montgomery, PhD

Global Head Regulatory CMC, GRAPSQA

AstraZeneca, United Kingdom

Susanne  Ausborn, PhD

Susanne Ausborn, PhD

Global Head International Regulatory Policy

Roche, Switzerland

The expansion of ICH brings the promise of more rapid access to medicines to a wider population of patients. It does though make the practicalities of harmonisation across a greater diversity of regulators more demanding. This is particularly the case in the CMC area where the detailed technical requirements not only impact the initial approval but ongoing future supply and accessibility for patients. This session will describe the work of the ICH members in the continued journey towards harmonisation, with some insight from newer members and an industry perspective on the continued opportunities to be tackled.

Speaker(s)

Frank  Montgomery, PhD

IQ Survey on Control Strategy Acceptance; Opportunity for further harmonisation

Frank Montgomery, PhD

AstraZeneca, United Kingdom

Global Head Regulatory CMC, GRAPSQA

Matt  Popkin, PhD

ICH Quality Discussion Group priorities

Matt Popkin, PhD

GSK, United Kingdom

Senior Director, CMC Excellence, Global Regulatory Affairs

Wassim  Nashabeh, PhD

Perspectives on progress to harmonisation from the ICH Assembly

Wassim Nashabeh, PhD

Genentech, A Member of the Roche Group, United States

Vice President, Global Head of Technical Regulatory Policy & International Ops

Raphael  Sanches Pereira

Reflections from ICH new Observers and Full Members

Raphael Sanches Pereira

ANVISA, Brazil

Quality Assessment of Synthetic Medicines Office Manager

Abdullah H. AL-Hatareshah, MSc, RPh

Reflections from ICH new Observers and Full Members

Abdullah H. AL-Hatareshah, MSc, RPh

Saudi Food and Drug Authority, Saudi Arabia

Executive Director for Regulatory Affairs

Yahya I. Al-Nujaym, MBA

Reflections from ICH new Observers and Full Members

Yahya I. Al-Nujaym, MBA

Saudi Food and Drug Authority, Saudi Arabia

Director for Standards

Milton  Bonelli, DrMed

Panel discussion and Q&A, with the additional participation of

Milton Bonelli, DrMed

European Medicines Agency, Netherlands

ICH Management Committee Member and Scientific Advice Officer

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.